82 related articles for article (PubMed ID: 25322921)
1. Gene expression analysis in tubule interstitial compartments reveals candidate agents for IgA nephropathy.
Wang J; Cao J
Kidney Blood Press Res; 2014; 39(4):361-8. PubMed ID: 25322921
[TBL] [Abstract][Full Text] [Related]
2. An emerging role of deubiquitinating enzyme cylindromatosis (CYLD) in the tubulointerstitial inflammation of IgA nephropathy.
Cui TG; Ichikawa T; Yang M; Dong X; Li J; Cui T
Biochem Biophys Res Commun; 2009 Dec; 390(2):307-12. PubMed ID: 19800320
[TBL] [Abstract][Full Text] [Related]
3. Identification of potential biomarkers and therapeutic targets for human IgA nephropathy and hypertensive nephropathy by bioinformatics analysis.
Cui Y; Liu S; Cui W; Gao D; Zhou W; Luo P
Mol Med Rep; 2017 Sep; 16(3):3087-3094. PubMed ID: 28713898
[TBL] [Abstract][Full Text] [Related]
4. Identification of key genes, pathways and potential therapeutic agents for IgA nephropathy using an integrated bioinformatics analysis.
Chen X; Sun M
J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320919635. PubMed ID: 32370650
[TBL] [Abstract][Full Text] [Related]
5. IgA Nephropathy Concomitant With Karyomegalic Interstitial Nephritis.
Wang Z; Ni X; Zhu S; Yue S
Am J Med Sci; 2020 Sep; 360(3):287-292. PubMed ID: 32387117
[TBL] [Abstract][Full Text] [Related]
6. [Expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in IgA nephropathy].
Wang J; Chen X; Shi S; Zhang Y; Tian Y
Zhonghua Nei Ke Za Zhi; 2002 Feb; 41(2):75-8. PubMed ID: 11940298
[TBL] [Abstract][Full Text] [Related]
7. Increased ACE and decreased ACE2 expression in kidneys from patients with IgA nephropathy.
Mizuiri S; Hemmi H; Arita M; Aoki T; Ohashi Y; Miyagi M; Sakai K; Shibuya K; Hase H; Aikawa A
Nephron Clin Pract; 2011; 117(1):c57-66. PubMed ID: 20689326
[TBL] [Abstract][Full Text] [Related]
8. Impact of interferon-gamma and interleukin-4 gene polymorphisms on development and progression of IgA nephropathy in Japanese patients.
Masutani K; Miyake K; Nakashima H; Hirano T; Kubo M; Hirakawa M; Tsuruya K; Fukuda K; Kanai H; Otsuka T; Hirakata H; Iida M
Am J Kidney Dis; 2003 Feb; 41(2):371-9. PubMed ID: 12552499
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of glomerulotubular crosstalk genes mediating IgA nephropathy by integrated bioinformatics.
Bai Y; Li Y; Xi Y; Ma C
BMC Nephrol; 2022 Apr; 23(1):143. PubMed ID: 35418061
[TBL] [Abstract][Full Text] [Related]
10. Association of the uteroglobin gene polymorphism with IgA nephropathy.
Matsunaga A; Numakura C; Kawakami T; Itoh Y; Kawabata I; Masakane I; Suzuki T; Suzuki M; Goto T; Itoh K; Hayasaka K
Am J Kidney Dis; 2002 Jan; 39(1):36-41. PubMed ID: 11774099
[TBL] [Abstract][Full Text] [Related]
11. Identification of differentially expressed genes and small molecule drugs for the treatment of tendinopathy using microarray analysis.
Cai X; Cai M; Lou L
Mol Med Rep; 2015 Apr; 11(4):3047-54. PubMed ID: 25502513
[TBL] [Abstract][Full Text] [Related]
12. [The role of tubulo-interstitial tissue damage in the progression of IgA glomerulonephritis].
Nagy J; Trinn C; Deák G; Schmelzer M; Burger T
Orv Hetil; 1984 Oct; 125(43):2615-6, 2619-20. PubMed ID: 6493769
[No Abstract] [Full Text] [Related]
13. [Expression of MCP-1 in renal tissues of patients with IgA nephropathy].
Sun Y; Yuan S; Xu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 34(10):1023-8. PubMed ID: 19893256
[TBL] [Abstract][Full Text] [Related]
14. [The association of single nucleotide P-selectin gene polymorphism with IgA nephropathy].
Wang ZH; Wang WM; Zhou T; Chen XN; Pan XX; Zhu J; Lu Y; Han B; Chen N
Zhonghua Nei Ke Za Zhi; 2006 Jul; 45(7):559-64. PubMed ID: 17074110
[TBL] [Abstract][Full Text] [Related]
15. C3, C4, factor B and HLA-DR alpha mRNA expression in renal biopsy specimens from patients with IgA nephropathy.
Oren R; Laufer J; Goldberg I; Kopolovic J; Waldherr R; Passwell JH
Immunology; 1995 Dec; 86(4):575-83. PubMed ID: 8567024
[TBL] [Abstract][Full Text] [Related]
16. Identification crucial genes in peripheral neuropathic pain induced by spared nerve injury.
Yang YK; Lu XB; Wang YH; Yang MM; Jiang DM
Eur Rev Med Pharmacol Sci; 2014; 18(15):2152-9. PubMed ID: 25070821
[TBL] [Abstract][Full Text] [Related]
17. Tenascin expression may reflect the activity and chronicity of human IgA nephropathy.
Masaki T; Yorioka N; Taniguchi Y; Oda H; Yamakido M
Clin Nephrol; 1998 Oct; 50(4):205-13. PubMed ID: 9799064
[TBL] [Abstract][Full Text] [Related]
18. Unveiling biomarkers and therapeutic targets in IgA nephropathy through large-scale blood transcriptome analysis.
Gan T; Qu LX; Qu S; Qi YY; Zhang YM; Wang YN; Li Y; Liu LJ; Shi SF; Lv JC; Zhang H; Peng YJ; Zhou XJ
Int Immunopharmacol; 2024 May; 132():111905. PubMed ID: 38552291
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting-enzyme inhibitors slow renal decline in IgA nephropathy, independent of tubulointerstitial fibrosis at presentation.
Kanno Y; Okada H; Yamaji Y; Nakazato Y; Suzuki H
QJM; 2005 Mar; 98(3):199-203. PubMed ID: 15728401
[TBL] [Abstract][Full Text] [Related]
20. [Relationship of mitogen-activated protein kinases activation with transdifferentiation of renal tubular epithelial cells in patients with IgA nephropathy].
Zhang M; Li XM
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):898-903. PubMed ID: 15329273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
